Viaskin milk patch vs placebo
Endoscopic improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
- no estimate extracted1 study · 20 participantsLow
Findings
What do systematic reviews say?
231 questions · 245 findings · 9 reviews · Gut
No studies found 76 · 31%GRADE not reported 3 · 1.2%Very low 106 · 43.3%Low 47 · 19.2%Moderate 12 · 4.9%High 1 · 0.4%
Viaskin milk patch vs placebo
Withdrawals due to adverse events · active EoE pediatric patients
Viaskin milk patch showed no clear difference in withdrawals due to adverse events at 44 weeks compared with placebo (low certainty).
1 finding from 1 review
- RR 1.12 [0.05, 23.99]1 study · 20 participantsLow
Leukotriene receptor antagonist vs placebo
Clinical improvement (dichotomous) · inactive EoE patients
It is very uncertain whether leukotriene receptor antagonist changes clinical improvement at 26 weeks (dichotomous) compared with placebo (very low certainty).
1 finding from 1 review
- RR 1.68 [0.66, 4.28]1 study · 41 participantsVery low
Infliximab 5–10 mg/kg vs placebo
Clinical remission · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 4.55 [1.53, 13.5]1 study · 80 participantsLow
Infliximab 5 mg/kg vs purine analogues
Clinical remission · Patients with active Crohn's disease
Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.5 [1.15, 1.95]2 studies · 355 participantsLow
Infliximab 5 mg/kg vs purine analogues
Clinical response at week 26 · Patients with active Crohn's disease
Infliximab 5 mg/kg may leads to higher clinical response at week 26 compared with purine analogues (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.44 [1.13, 1.82]2 studies · 355 participantsLow
Infliximab 5 mg/kg vs purine analogues
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 0.7 [0.46, 1.06]2 studies · 355 participantsLow
Infliximab 5 mg/kg vs infliximab 10 mg/kg
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.79 [1.06, 3.02]1 study · 55 participantsVery low
Infliximab 5 mg/kg vs infliximab 10 mg/kg
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction in CDAI by 70 points at week 4 compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.63 [1.08, 2.46]1 study · 55 participantsVery low
Infliximab 5 mg/kg vs infliximab 10 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.03 [0.07, 15.79]1 study · 63 participantsVery low
Infliximab 5 mg/kg vs infliximab 10 mg/kg
Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.46 [0.84, 2.53]1 study · 63 participantsVery low
Infliximab 5 mg/kg vs infliximab 10 mg/kg
Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.2 [0.82, 1.78]1 study · 63 participantsVery low
Infliximab 5 mg/kg vs infliximab 20 mg/kg
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.79 [1.06, 3.02]1 study · 55 participantsVery low
Infliximab 5–10 mg/kg vs placebo
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical response defined as improvement in the scores on the CDAI… compared with placebo (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 4.09 [1.63, 10.25]1 study · 80 participantsLow
Infliximab 5 mg/kg vs infliximab 20 mg/kg
Clinical response as defined by the studies week 4 · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response as defined by the studies week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1.27 [0.91, 1.76]1 study · 55 participantsVery low
Infliximab 5 mg/kg vs infliximab 20 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Infliximab 10 mg/kg vs infliximab 20 mg/kg
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 10 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 1 [0.52, 1.92]1 study · 56 participantsVery low
Infliximab 10 mg/kg vs infliximab 20 mg/kg
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
It is very uncertain whether infliximab 10 mg/kg changes clinical response defined by reduction of CDAI score by ≥ 70 at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 0.78 [0.49, 1.23]1 study · 56 participantsVery low
Infliximab 10 mg/kg vs infliximab 20 mg/kg
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Infliximab 5 mg/kg vs CT‐P13 biosimilar 5 mg/kg
Clinical remission · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in clinical remission defined as CDAI < 150 at week 6 compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
- Infliximab for medical induction of remission in Crohn's disease 2023 · Cochrane Headline outcomes onlyRR 0.98 [0.72, 1.32]1 study · 220 participantsLow